BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 27725933)

  • 1. Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury.
    Lin C; Khetani SR
    Biomed Res Int; 2016; 2016():1829148. PubMed ID: 27725933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening.
    Gómez-Lechón MJ; Tolosa L
    Arch Toxicol; 2016 Sep; 90(9):2049-2061. PubMed ID: 27325232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of Drug-Induced Liver Injury in Micropatterned Co-cultures Containing iPSC-Derived Human Hepatocytes.
    Ware BR; Berger DR; Khetani SR
    Toxicol Sci; 2015 Jun; 145(2):252-62. PubMed ID: 25716675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.
    Gómez-Lechón MJ; Tolosa L; Donato MT
    J Appl Toxicol; 2016 Jun; 36(6):752-68. PubMed ID: 26691983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
    Zhang J; Doshi U; Suzuki A; Chang CW; Borlak J; Li AP; Tong W
    Chem Biol Interact; 2016 Aug; 255():3-11. PubMed ID: 26581450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current limitations and future opportunities for prediction of DILI from in vitro.
    Funk C; Roth A
    Arch Toxicol; 2017 Jan; 91(1):131-142. PubMed ID: 27766365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity evaluation using cryopreserved primary human hepatocytes in various culture formats.
    Richert L; Baze A; Parmentier C; Gerets HHJ; Sison-Young R; Dorau M; Lovatt C; Czich A; Goldring C; Park BK; Juhila S; Foster AJ; Williams DP
    Toxicol Lett; 2016 Sep; 258():207-215. PubMed ID: 27363785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The application of engineered liver tissues for novel drug discovery.
    Lin C; Ballinger KR; Khetani SR
    Expert Opin Drug Discov; 2015 May; 10(5):519-40. PubMed ID: 25840592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The application of omics-based human liver platforms for investigating the mechanism of drug-induced hepatotoxicity in vitro.
    Jiang J; Pieterman CD; Ertaylan G; Peeters RLM; de Kok TMCM
    Arch Toxicol; 2019 Nov; 93(11):3067-3098. PubMed ID: 31586243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphological and Functional Characterization and Assessment of iPSC-Derived Hepatocytes for In Vitro Toxicity Testing.
    Lu J; Einhorn S; Venkatarangan L; Miller M; Mann DA; Watkins PB; LeCluyse E
    Toxicol Sci; 2015 Sep; 147(1):39-54. PubMed ID: 26092927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of in vitro combination assays of mitochondrial dysfunction and apoptosis for the estimation of potential risk of idiosyncratic drug induced liver injury.
    Goda K; Takahashi T; Kobayashi A; Shoda T; Kuno H; Sugai S
    J Toxicol Sci; 2016; 41(5):605-15. PubMed ID: 27665770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct and indirect contribution of human embryonic stem cell-derived hepatocyte-like cells to liver repair in mice.
    Woo DH; Kim SK; Lim HJ; Heo J; Park HS; Kang GY; Kim SE; You HJ; Hoeppner DJ; Kim Y; Kwon H; Choi TH; Lee JH; Hong SH; Song KW; Ahn EK; Chenoweth JG; Tesar PJ; McKay RD; Kim JH
    Gastroenterology; 2012 Mar; 142(3):602-11. PubMed ID: 22138358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-Culture of Human Primary Hepatocytes and Nonparenchymal Liver Cells in the Emulate® Liver-Chip for the Study of Drug-Induced Liver Injury.
    Shi Q; Arefin A; Ren L; Papineau KS; Barnette DA; Schnackenberg LK; Hawes JJ; Avigan M; Mendrick DL; Ewart L; Ronxhi J
    Curr Protoc; 2022 Jul; 2(7):e478. PubMed ID: 35790095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microengineered liver tissues for drug testing.
    Khetani SR; Berger DR; Ballinger KR; Davidson MD; Lin C; Ware BR
    J Lab Autom; 2015 Jun; 20(3):216-50. PubMed ID: 25617027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional profiling suggests that Nevirapine and Ritonavir cause drug induced liver injury through distinct mechanisms in primary human hepatocytes.
    Terelius Y; Figler RA; Marukian S; Collado MS; Lawson MJ; Mackey AJ; Manka D; Qualls CW; Blackman BR; Wamhoff BR; Dash A
    Chem Biol Interact; 2016 Aug; 255():31-44. PubMed ID: 26626330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-silico approach for drug induced liver injury prediction: Recent advances.
    Saini N; Bakshi S; Sharma S
    Toxicol Lett; 2018 Oct; 295():288-295. PubMed ID: 29981923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of hepatotoxic drugs in human hepatocytes from multiple donors: Identification of P450 activity as a potential risk factor for drug-induced liver injuries.
    Utkarsh D; Loretz C; Li AP
    Chem Biol Interact; 2016 Aug; 255():12-22. PubMed ID: 26718876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissecting the molecular pathophysiology of drug-induced liver injury.
    Ye H; Nelson LJ; Gómez Del Moral M; Martínez-Naves E; Cubero FJ
    World J Gastroenterol; 2018 Apr; 24(13):1373-1385. PubMed ID: 29632419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of immune reactions in drug-induced liver injury (DILI).
    Ju C; Reilly T
    Drug Metab Rev; 2012 Feb; 44(1):107-15. PubMed ID: 22235834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-Induced Liver Injury and Individual Cell Models.
    Benesic A; Gerbes AL
    Dig Dis; 2015; 33(4):486-91. PubMed ID: 26159263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.